Pruritis Clinical Trial
Official title:
A Randomized Prospective, Double-Blind Placebo Controlled Study of Oral Ergocalciferol in the Treatment of Pruritis in Hemodialysis Patients
Pruritis (itching) is common in many people with chronic renal failure on hemodialysis.
There may be many different reasons for the pruritis. Efforts to treat the problem have not
been very effective.
Vitamin D levels have been found to be low in many hemodialysis patients. Since vitamin D
plays an important role in the skin and is effective in treatment of certain skin conditions
that involve pruritis, it may have a role in treatment of pruritis in hemodialysis patients.
The objective of the investigators study is to determine the effect of supplementation with
oral vitamin D2 (ergocalciferol) on pruritis in hemodialysis patients.
Vitamin D2 is a fat soluble steroid hormone precursor which must be hydroxylated in the liver and kidney respectively to make the active form 1-25-Vitamin D. This active metabolite and related analogs have been synthesized and are frequently used in the treatment of hyperparathyroidism in patients with chronic kidney disease. However the active metabolite may not be back metabolized to the precursor forms which may have functions in other organs including the skin. Supplementation of hemodialysis patients with oral vitamin D forms would provide a source of precursors for use throughout the body. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04518618 -
Effect of Intrathecal Naloxone in the Incidence of Pruritis After C.S
|
N/A | |
Completed |
NCT00693654 -
Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients
|
Phase 4 | |
Completed |
NCT00323154 -
Nalbuphine for the Treatment of Opioid Induced Pruritus in Children
|
Phase 3 | |
Completed |
NCT03816891 -
Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis
|
Phase 2 | |
Recruiting |
NCT05936567 -
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
|
Phase 2 | |
Not yet recruiting |
NCT06226610 -
Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
|
Phase 2 | |
Withdrawn |
NCT02909569 -
Relieving Chronic Itch: Oral Medication
|
Phase 2 |